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Abstract
Background: Antigen-specific IFN-c producing CD4
+ T cells are the main mediators of protection against Mycobacterium
tuberculosis infection both under natural conditions and following vaccination. However these cells are responsible for lung
damage and poor vaccine efficacy when not tightly controlled. Discovering new tools to control nonprotective antigen-
specific IFN-c production without affecting protective IFN-c is a challenge in tuberculosis research.
Methods and Findings: Immunization with DNA encoding Ag85B, a candidate vaccine antigen of Mycobacterium
tuberculosis, elicited in mice a low but protective CD4
+ T cell-mediated IFN-c response, while in mice primed with DNA and
boosted with Ag85B protein a massive increase in IFN-c response was associated with loss of protection. Both protective
and non-protective Ag85B-immunization generated antigen-specific CD8
+ T cells which suppressed IFN-c-secreting CD4
+ T
cells. However, ex vivo ligation of 4-1BB, a member of TNF-receptor super-family, reduced the massive, non-protective IFN-c
responses by CD4
+ T cells in protein-boosted mice without affecting the low protective IFN-c-secretion in mice immunized
with DNA. This selective inhibition was due to the induction of 4-1BB exclusively on CD8
+ T cells of DNA-primed and
protein-boosted mice following Ag85B protein stimulation. The 4-1BB-mediated IFN-c inhibition did not require soluble IL-
10, TGF-b, XCL-1 and MIP-1b. In vivo Ag85B stimulation induced 4-1BB expression on CD8
+ T cells and in vivo 4-1BB ligation
reduced the activation, IFN-c production and expansion of Ag85B-specific CD4
+ T cells of DNA-primed and protein-boosted
mice.
Conclusion/Significance: Antigen-specific suppressor CD8
+ T cells are elicited through immunization with the
mycobacterial antigen Ag85B. Ligation of 4-1BB receptor further enhanced their suppressive activity on IFN-c-secreting
CD4
+ T cells. The selective expression of 4-1BB only on CD8
+ T cells in mice developing a massive, non-protective IFN-c
response opens novel strategies for intervention in tuberculosis pathology and vaccination through T-cell co-stimulatory-
based molecular targeting.
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Introduction
Tuberculosis (TB) remains a leading human infectious disease
and a major public health problem in low-income countries [1].
Despite the availability of the Bacillus Calmette-Guerin (BCG)
vaccine for more than 80 years, until now an effective
tuberculosis vaccine is still far to be generated and still unknown
are the correlates of protection against this disease [2]. There is a
remarkable body of evidence that IFN-c producing CD4
+ Tc e l l s
are the main mediators of protection against Mycobacterium
tuberculosis (MTB) infection both under natural conditions and
following vaccination [3,4]. However, while activated CD4
+ T
cells are required to avoid the spread of MTB during infection,
they can also cause severe inflammation with collateral tissue
damage when not tightly controlled [5,6]. Granuloma necrosis in
a mouse model of MTB-induced pulmonary immunopathology is
due to IFN-c and T cells expressing the ab T cell receptor [7].
Moreover IFN-c-producing CD4
+ T cells can interfere with
development of protective immunity during experimental vacci-
nation with mycobacterial antigens [8–10], including Ag85B, an
abundant secreted protein of replicating MTB which is currently
evaluated in various TB vaccine formulations [2,11–13]. It has
been recognized that activation of Ag85B-specifc CD4
+ Tc e l l si n
TB patients is not always associated with a favourable prognosis
[14,15], and that frequencies of Ag85-specific IFN-c-secreting
CD4
+ T cells correlate with bacterial load rather than with
degree of protection in MTB-infected mice [16]. The massive
deleterious inflammation observed in the Koch phenomenon
[17], which involves Ag85B among other antigens, is a primary
example of de-regulated cell-mediated response to mycobacterial
antigens. Thus, discovering how to control non protective
antigen-specific IFN-c production without affecting secretion of
protective IFN-c is an important challenge in tuberculosis
research.
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11019Regulatory T cells (Treg) limit the magnitude of effector
responses. Despite the little role played by inactivation of natural
CD4
+CD25
+ Treg cells in improving protective BCG immunity
[18], several reports indicate that pathogen-specific Treg cells,
mainly IL-10-secreting CD4
+CD25
+ Tr1, are generated following
MTB infection and suppress IFN-c cell responses in anergic TB




which can inhibit CD4
+ T cell responses has also been described
in purified protein derivative (PPD)
+ subjects, but the clinical
significance of this lymphocyte subset is still unknown [24]. The
induction of Treg cells upon vaccination with mycobacterial
antigen and the immunological mechanisms which regulate their
functions need to be further investigated.
Co-stimulatory molecules are up-regulated by activated T cells
and participate in regulation of T cell functions. 4-1BB, the
murine homologue of human CD137, is a member of the TNF-
receptor super-family [25] expressed primarily on antigen-receptor
activated T cells [26,27]. Although 4-1BB co-stimulates primary
and secondary responses of both CD8
+ and CD4
+ T effector cells
[28–31], signalling via this molecule also results in the activation of
CD4
+ Treg cells in vitro [32] and in the generation of CD8
+ Treg
cells that suppress CD4
+ T cell function and antibody responses in
vivo [33,34]. Due to their ability to activate both effector and
regulatory T cells, 4-1BB/CD137 ligands are being evaluated for
treatment of cancer and auto-immune diseases [35].
We have previously reported that protection conferred by
immunization of mice with an Ag85B-encoding plasmid DNA was
lost when DNA-primed mice were boosted with adjuvant-free
Ag85B protein [10]. The lack of protection was associated with the
expansion of an Ag85B-specific CD4
+ T cell subset secreting
elevated IFN-c amounts that caused loss or dilution of protective
low IFN-c secreting-CD4
+ T cells elicited by DNA immunization
[10]. Co-administration of Ag85B protein with the adjuvant
LTK63 reduced the generation/polarization of Ag85B-specific
IFN-c secreting cells and resulted in some recovery of protection
[36]. Thus, manipulating the IFN-c production by antigen-specific
CD4
+ T cells may achieve a proper balance between protection
and pathology and have vaccine-relevant implication.
In the present study, we asked whether it was possible to
modulate antigen-specific, IFN-c producing CD4
+ T cells not in
the induction phase, as mentioned above, but after they have been
generated. Namely, we used the previously established TB model
of protective Ag85B DNA- and non-protective Ag85B DNA/
protein- immunizations to investigate the role played by CD8
+ T
cells and 4-1BB ligation on controlling memory Ag85B-specific
IFN-c-secreting CD4
+ T cells. We found that both protective and
non-protective Ag85B-immunization generated antigen-specific
CD8
+ T cells that suppressed Ag85B-specific IFN-c-secreting
CD4
+ T cells. 4-1BB ligation selectively reduced the high but non-
protective CD4
+ T cell-mediated IFN-c response in DNA-primed
and protein-boosted mice without affecting the low IFN-c
response associated with protection in mice vaccinated with
DNA. The 4-1BB-mediated IFN-c inhibition selectively in spleen
cells of DNA-primed and protein-boosted mice was linked to the
induction of 4-1BB exclusively on CD8




+ T cells reduce Ag85B-mediated IFN-c production by
antigen-specific CD4
+ T cells elicited through protective
and non-protective Ag85B-immunizations
Previously, we reported that mice immunized with Ag85B-
encoding DNA were protected against MTB challenge (P-mice)
while adjuvant-free Ag85B protein boosting in mice primed with
Ag85B-encoding DNA (NP-mice) did not confer protection (10,
36). The lack of protection in NP-mice was associated with an
excessive Ag85B-induced IFN-c production by spleen cells (10). In
spleen cells of both NP- and P-mice CD4
+ T cell depletion almost
abolished the IFN-c release indicating that IFN-c production in
response to Ag85B stimulation was mainly attributable to CD4
+ T
cells. On the other hand, depletion of CD8
+ T cells induced a
significant increase of IFN-c secretion, suggesting that CD8
+ T
cells may exert a negative control on antigen-specific IFN-c
secreting CD4
+ T cells (10). To verify this hypothesis, CD4
+ and
CD8
+ T cells of NP- and P-mice were purified through negative
selection and cultured on a feeder of CD3
+ T cell-depleted spleen
cells from naı ¨ve mice. CD4
+ T cells of NP- and P-mice, (but not
naı ¨ve CD4
+ T cells used as control, data not shown) secreted IFN-
c in response to Ag85B protein stimulation maintaining the
differences in magnitude observed on unfractionated spleen cells
(Fig. 1 A and B). When purified CD8
+ T cells of NP- or P-mice
were added to their respective CD4
+ T cells a significant inhibition
of Ag85B-mediated IFN-c secretion was observed (Fig. 1 A and B),
indicating that CD8
+ T cells exert suppressing activity on antigen-
specific CD4
+ T cells. Since CD8
+ T cells recovered from naı ¨ve
mice were unable to inhibit Ag85B-mediated IFN-c secretion by
CD4
+ T cells of NP- and P- mice (Fig. 1 A and B), it is likely that
these CD8
+ T cells with suppressive activity were generated during
Ag85B immunization. Purified CD8
+ T cells of both naı ¨ve and
Ag85B-immunized mice or cells used as feeder did not release
detectable amounts of IFN-c (data not shown).
4-1BB ligation inhibits Ag85B-mediated IFN-c production
by CD4
+ T cells exclusively in spleen cells of NP-mice:
CD8
+ T cells are required for inhibition
Since signals through the T cell co-stimulatory molecule 4-1BB
expressed by activated T cells can modulate both effector and
regulatory T cell functions [28–34], the effects induced by 4-1BB
ligation on Ag85B-mediated-IFN-c production were studied in
antigenic recall experiments with spleen cells of P- and NP-mice.
In spleen cells of NP-mice stimulated with Ag85B protein,
treatment with an agonistic anti-4-1BB mAb reduced the
excessive/non-protective accumulation of IFN-c in culture
supernatants (Fig. 2 A and B). The lack of IFN-c production
when CD4
+ T cell were removed from spleen cells (Fig. 2A)
suggested that the 4-1BB-mediated inhibition affected the IFN-c
secretion by antigen-specific CD4
+ T cells. This hypothesis was
clearly confirmed by the consistent reduction in the percentage
and fluorescence intensity of IFN-c-producing CD4
+ T cells in
Ag85B-stimulated spleen cells treated with an agonistic anti-4-1BB
mAb after 4 days of culture (Fig. 2 C and Table 1). The reduction
of antigen-mediated IFN-c accumulation in supernatants peaked
at 5 days (about 48% of inhibition) (Fig. 2 B). The inhibitory effects
mediated by 4-1BB ligation required CD8
+ T cells since it was lost
when those cells were removed from the cultures (Fig. 2 A and B),
suggesting an involvement of the suppressor CD8
+ T
cells generated during Ag85B-vaccination in this regulatory
mechanisms.
In spleen cells of P-mice, 4-1BB ligation did not reduce either
the modest IFN-c release by CD4
+ T cells of P-mice stimulated
with Ag85B protein - as indicated by ELISA measurement in
culture supernatant of spleen cells (Fig. 2 E and F) - or the number
of Ag85B-stimulated IFN-c producing CD4
+ T cells at 4 days of
culture, as indicated by intracellular staining (Fig. 2 G and
Table 1). Therefore, although suppressor CD8
+ T cells were
generated in spleens of both NP- and P-mice, 4-1BB ligation,
through CD8
+ T cells, reduced exclusively the massive, non-
4-1BB and IFN-c in TB
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+ T cells of
NP-mice while did not modify the modest antigenic secretion by
CD4
+ T cells of P-mice.
The capacity of 4-1BB signalling to inhibit Ag85B-mediated
IFN-c production by CD4
+ T cells of NP-mice was antigen-
restricted. Indeed, in spleen cells of both P and NP-mice, agonistic
anti-4-1BB mAb treatment increased the amount of IFN-c
secreted upon activation through CD3e engagement on T cells
(Fig. 2 D and H). The up-regulation of CD3e-mediated IFN-c
production affected both CD8
+ (the more responsive population)
and CD4
+ T cells, as suggested by in vitro depletion studies (Fig. 2
D and H). Therefore, 4-1BB acted as the expected co-stimulatory




Ag85B stimulation induces expression of 4-1BB on CD8
+
T cells exclusively in spleen cells of NP-mice
In order to explain the responsiveness of spleen cells of NP-mice
to 4-1BB ligation, we analyzed whether Ag85B stimulation could
induce the expression of this TNF-receptor on T cells. In spleen
cells of NP-mice induction of 4-1BB expression was found on a
sub-population of CD4
+ T cells when splenocytes were stimulated
for 3 days with Ag85B protein (Fig. 3 A and Table 2). 4-1BB
expression on CD4
+ T cells was maintained after 6 days of culture.
In spleen cells of P-mice activated with Ag85B protein a smaller
percentage of CD4
+ T cells, as compared to Ag85B-activated
CD4
+ T cells of NP-mice, expressed 4-1BB after 3 days of culture.
However, after 6 days of culture no significant expression of this
receptor was found on CD4
+ T cells of P-mice (Fig. 3 A and
Table 2).
In spleen cells of NP-mice Ag85B protein stimulation caused the
induction of 4-1BB on a small subset of CD8
+ T cells after 3 days
of culture and the percentage of 4-1BB
+CD8
+ T cells even
increased after 6 days of culture (Fig. 3 B and Table 2). Therefore,
in response to antigen, some CD4
+ and CD8
+ T cells of NP-mice
became responsive to ligands for 4-1BB. On the other hand, no
significant induction of 4-1BB was found on CD8
+ T cells in
spleen cells of P-mice activated with Ag85B protein after 3 or 6
days of culture (Fig. 3 B and Table 2).
Effect of 4-1BB ligation on modulation of CD4
+ and CD8
+
T cell surface marker expression in Ag85B-activated
spleen cells of NP mice
Next, the effects of 4-1BB ligation on the phenotype of both
CD4
+ and CD8
+ T cells was studied in culture of spleen cells of
NP- or P- mice stimulated with Ag85B protein. In particular, the
expression of T cell activation markers expressed upon TCR
complex stimulation such as CD25, the IL-2Ra, CD38, an
ectoenzyme with cyclase and hydrolase enzymatic activity,
CD233, an MHC class II binding CD4 homologue, and CD44,
an adhesion molecule expressed by activated memory T cells, was
analyzed. All these markers are up-regulated by both activated
effector and regulatory cells [21,23,32–34,37–41].
In spleen cells of NP-mice Ag85B protein stimulation induced
up-regulation of CD25, CD38, CD233 and CD44 on about 40%
of CD4
+ T cells (Table 3). Likely these CD4
+ T cells were effectory
memory cells in view of the low expression of CD62L (data not
shown). Upon agonistic anti-4-1BB mAb treatment, CD4
+ T cells
of NP-mice down-modulated surface expression of all activated T
cell markers, suggesting a reduced activation of antigen-specific
CD4
+ T cells following agonistic anti-4-1BB mAb treatment.
In spleen cells of P-mice, Ag85B stimulation induced a weak up-
regulation of CD25, CD38, CD233 and CD44 expression on
CD4
+ T cells (Table 3). These data were consistent with a reduced
activation of CD4
+ T cells of P-mice compared to CD4
+ T cells of
NP-mice upon Ag85B protein stimulation. Moreover, agonistic
anti-4-1BB mAb treatment did not influence the phenotype of
Ag85B-activated CD4
+ T cells.
In spleen cells of both P- and NP-mice Ag85B protein
stimulation led to up-regulation of CD233 on a subset of CD8
+
T cells, while no changes were observed in the percentage of cells
expressing CD25, CD38 and CD44 (Table 4). Agonistic anti-4-
Figure 1. Role of CD8
+ T cells in modulating Ag85B-mediated
IFN-c secretion associated with protection and non-protection
against MTB infection. Untouched purified CD4
+ T cells (5610
4 cells/
well) and CD8
+ T cells (3610
4 cells/well) obtained by negative magnetic
bead separation as described in Materials and Methods from spleen
cells of NP-mice (panel A) or P-mice (panel B) were cultured, alone or
together (using the CD4/CD8 ratio of 1:0.6 as found in fresh spleen cells)
on a feeder of CD3
+ T cell-depleted spleen cells of naive mice (1.5610
5
cells/well). Untouched purified CD8
+ T cells recovered from naı ¨ve
unvaccinated (3610
4 cells/well) were also added to CD4
+ T cell co-
culture. Cells were re-stimulated with Ag85B protein (5 microg/ml).
Culture supernatants were harvested after 3 days for IFN-g detection by
a specific quantitative sandwich ELISA Kit. Data are presented as mean
of 4 independent experiments. Error bars indicate SEM. The level of
statistical significance for differences were determined by a two-tailed
Student t test (**, p,0.01) between Ag85B-induced responses by CD4
+
T cells alone and co-cultured with CD8
+ T cells. Purified CD8
+ T cells of
both naı ¨ve and Ag85B-immunized mice or cells used as feeder did not
release detectable amounts of IFN-g (data not shown).
doi:10.1371/journal.pone.0011019.g001
4-1BB and IFN-c in TB
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11019Figure 2. 4-1BB ligation in spleen cells of NP-mice but not of P-mice reduces IFN-c production by Ag85B-specific CD4
+ T cells. Pooled
spleen cells, unfractionated or depleted of CD4
+ or CD8
+ T cells by using magnetic beads as described in Materials and Methods of NP-mice (panels
A–D) or P-mice (panels E–H) were re-stimulated with Ag85B protein (5 mg/ml) (panels A–C, E–G) or anti-CD3e mAb (0.1 mg/ml) (panels D and H) in the
presence of agonistic anti-4-1BB mAb or rat IgG2a control Ab (5 mg/ml each). In panels A, E, D and H, the amount of IFN-c released in the culture
supernatants after 3 days was detected by a commercial ELISA kit and the data has been reported as the mean of 5 independent experiment. In
panels B and F the percentage of inhibition of Ag85B-induced IFN-c release by an agonistic anti-4-1BB mAb in unfractionated or CD8
+ T cell-depleted
4-1BB and IFN-c in TB
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exclusively on CD8
+ T cells of NP-mice.
4-1BB ligation has opposite effects on cell proliferation in
spleen of NP-mice stimulated with Ag85B: reducing
proliferation of CD4
+ T cells while enhancing that of
CD8
+ T cells
In order to analyze the effects of 4-1BB ligation on CD4
+ and
CD8
+ T cell proliferation of NP- and P-mice, the CFSE labelled
spleen cells were stimulated with Ag85B protein for 4 days.
In spleen cells of NP-mice, Ag85B protein stimulation induced a
remarkable CD4
+ T cell proliferation as indicated by CFSE
dilution (Fig. 4 and Table 1). Treatment with an agonistic anti-4-
1BB mAb significantly reduced the number of proliferating CD4
+
T cells (Fig. 4 and Table 1). These data are consistent with the
reduced expression of activation markers observed on Ag85B-
activated CD4
+ T cells of NP-mice following 4-1BB ligation
(Table 3). Ag85B protein stimulation also induced CD8
+ T cell
proliferation. However, the number of proliferating CD8
+ T cells
increased in the presence of the agonistic anti-4-1BB mAb
treatment, suggesting that the subset of CD8
+ T cells expressing
4-1BB may be expanded by a direct engagement of this receptor
(Fig. 4 and Table 1).
In spleen cells of P-mice, Ag85B-stimulation induced a lower
CD4
+ T cell proliferation as compared to that observed in CD4
+ T
cells of NP-mice while the number of proliferating CD8
+ T cells
were similar in the two groups of immunized mice (Fig. 4 and
Table 1). Agonistic anti-4-1BB mAb treatment had only a little
influence on CD4
+ or CD8
+ T cell proliferation in P-mice (Fig. 4
and Table 1). These data are consistent with the low or absent
expression of 4-1BB on CD4
+ T and CD8
+ T cells of P-mice.
Effects of 4-1BB ligation on cytokine/chemokine
production in Ag85B-stimulated spleen cells of NP-mice
We next asked whether 4-1BB signalling could modulate
Ag85B-mediated production of other cytokines, besides IFN-c,
playing a recognized positive or negative role in protection
against MTB. Cytokine/chemokines such IL-10, TGF-b, MIP-
1b and XCL-1 capable to inhibit the IFN-c production by
CD4
+ T cells [24,42–44] were also analyzed to address the
mechanisms of 4-1BB-mediated IFN-c inhibition. In spleen cells
of NP-mice, the low Ag85B-induced secretion of IL-2 and TNF-
a, Th1 associate cytokines was preserved in the presence of
agonist anti-4-1BB mAb (Fig. 5 A). Also IL-6 release induced by
Ag85B protein stimulation was unaffected by agonist anti-4-1BB
mAb treatment (Fig. 5 A). 4-1BB ligation did not induce
production of IL-4, a Th2 cytokine, IL-17, a cytokine which
contribute to protection to MTB challenge [45,46] and XCL-1,
a chemokine released by suppressor CD8
+ T cells during the
chronic stage of infection with MTB that negatively affects
production of IFN-c by CD4
+ T cells [44]. None of the
cytokines above were released upon Ag85B stimulation
(Fig. 5 A). Although no further secreted in response to antigenic
stimulation, some TGF-b, a potent cytokine suppressing Th1
function [38], was nonetheless found in spleen cell cultures
(Fig. 5 A). Hence, to exclude any involvement of TGF-b in
4-1BB-mediated inhibition of IFN-c, an anti-TGFb neutralizing
mAb was added to unfractionated spleen cell culture of NP-mice
stimulated with Ag85B protein and agonistic anti-4-1BB mAb.
Also in this condition, the ability of 4-1BB ligation to reduce
Ag85B-induced IFN-c secretion was unchanged (Fig. 5 E).
On the other hand, 4-1BB ligation decreased the accumulation
of IL-10 and MIP-1b (Fig. 5 B and C). Since soluble forms of IL-
10 and MIP-1b can both control IFN-c production [19,23,24,42]
the reduced level of these factors found following 4-1BB ligation
did not fit with a their involvement in 4-1BB-mediated IFN-c
inhibition. IL-10 was exclusively produced by CD4
+ T cells upon
Ag85B stimulation in total spleen cells (Fig. 5 C and D) and 4-1BB-
ligation reduced IL-10 production by Ag85B-stimulated CD4
+ T
cells as shown in intracellular staining (Fig. 5 D). IL-10-producing
CD4
+ T cells did not produce IFN-c (data not shown), indicating
Table 1. Effects of 4-1BB ligation in spleen cells of NP- and P-
mice stimulated with Ag85B protein on IFN-c-producing CD4
+













unstimulated 0.3260.02 0.1660.3 4.060.5 3.560.5
Ag85B/control IgG 5.260.6# 0.9560.02# 39.863# 12.061#
Ag85B/anti-
4-1BB mAb
2.660.31 0.6760.031 24.560.51 19.360.91
P-mice
unstimulated 0.1460.02 nd 2.760.4 5.260.9
Ag85B/control IgG 0.6260.06# nd 12.361.9# 14.261.6#
Ag85B/anti-
4-1BB mAb
0.460.13 nd 10.761.8 15.062.3
To analyze IFN-c- or IL-10-producing CD4
+ T cells, unfractionated spleen cells of
P- or NP-mice were cultured with Ag85B protein (5 mg/ml) in the presence of
IgG2a control Ab or agonist anti-4-1BB mAb (5 mg/ml). After 2 days (for IL-10
analysis) or 4 days (for IFN-c analysis) of culture and an overnight incubation
with brefeldin A cells were stained with CD4-PE-Cy5 and then intracellular
stained with PE anti-IL-10 or FITC anti-IFN-c Ab as reported in Material and
Methods. Cells were then analyzed by flow cytometry and the data show
frequency of IFN-c- or IL-10-producing CD4
+ T cells.
To study cell proliferation, unfractionated spleen cells of NP- or P-mice, were
labelled with CFSE as described in Materials and Methods and then stimulated
with Ag85B protein (5 mg/ml) in the presence of agonistic anti-4-1BB mAb
(5 mg/ml) or rat IgG2a control Ab (5 mg/ml) for 4 days. At this time point cells
were labelled with CD4-PE and CD8-PerCP and analyzed by flow cytometry as









The results are presented as mean 6 SEM of the percentage of CD4
+ T cells or
CD8
+ T cells staining for the indicated markers. Pooled data of 3 independent
experiments are shown.
#, 1 statistical significance for differences between groups determined by
ANOVA and Bonferroni-type multiple t-test (# Ag85B/control IgG vs
unstimulated; 1 Ag85B/control IgG vs Ag85B/anti-4-1BB mAb).
nd=not done.
doi:10.1371/journal.pone.0011019.t001
spleen population after 3 or 5 days of culture has been reported as the mean of 12 independent experiments for NP-mice and of 8 independent
experiments for P-mice. Rat IgG2a control Ab did not modified the cell proliferation or IFN-c secretion after stimulation with Ag85B and anti-CD3e
mAb (data not shown). Error bars indicate SEM. The level of statistical significance for differences between groups were determined by a two-tailed
Student t test (*, p,0.05; **, p,0.01). In panels C and G, spleen cells of both NP- or P-mice after 4 days of culture and an overnight incubation with
brefeldin A were stained with CD4-PE-Cy5 and then intracellular stained with FITC anti-IFN-c Ab as reported in Material and Methods. Cells were then
analyzed by flow cytometry. Dot plot were generated after gating on live CD4
+ T lymphocytes and show frequency of IFN-c-producing cells. The rat
IgG2a control Ab did not significantly change Ag85B-induced IFN-c secretion by spleen cells of NP-mice (data not shown).
doi:10.1371/journal.pone.0011019.g002
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CD4
+ T cell subsets secreting IL-10 or IFN-c were present. Since
secretion of MIP-1b was in part due to cells other than CD4
+T-
cells (Fig. 5 B), the possibility of MIP-1b secretion by CD8
+ T cells
was supposed. In any case 4-1BB ligation did not modulate the
release of MIP-1b by non-CD4
+ T cells (Fig. 5 B).
Moreover, unlike IFN-c, CD4
+ T cell-mediated production of
IL-10 and MIP-1b decreased in a CD8
+ T cell-independent
manner upon 4-1BB ligation (Fig. 5 B and C), suggesting that in
Ag85B-responding CD4
+ T cells the regulatory mechanisms
controlling secretion of IFN-c differ compare to those modulating
other cytokines influential in TB protection.
In addition to cytokines, some metabolic products which affect
tryptophan metabolism play a role in inhibition of T cell responses.
In particular, the tryptophan catabolising enzyme indoleamine-
pyrrole 2,3dioxygenase (IDO) leads to the inhibitionof CD4
+ T cell
responses when up-regulated by an agonistic 4-1BB mAb in
macrophages and dendritic cells [34,47]. To test IDO functions we
used 1-methyltryptophan (1-MT), which abrogates 4-1BB-con-
trolled IDO-mediated immune suppression [47]. When 1-MT was
added to unfractionated spleen cellculture of NP-mice, the ability of
4-1BB ligation to reduce Ag85B-induced IFN-c secretion was
unchanged (Fig. 5 E). However, 1-MT treatment induced increased
IFN-c levels in Ag85B-stimulated cells independent of treatment
Figure 3. Ag85B protein stimulation in spleen cells of NP-mice induces expression of 4-1BB on both CD4
+ and CD8
+ T cells. Pooled
spleen cells of NP-mice (panel A) or P-mice (panel B) were re-stimulated with Ag85B protein (5 mg/ml). After 3 or 6 days of cultures, cells were labelled
with the following mAb: CD4 PE-Cy7, CD8 PE-Cy7, CD3 FITC and 4-1BB PE. Cell surface molecule expression was analyzed by flow cytometry as
described in Materials and Methods. Within each panel, the percentage indicates the number of cells expressing the 4-1BB receptor. Plots, gated on
CD4
+ or CD8
+ T cells in the lymphocyte-gate, are representative of one experiments out of 3.
doi:10.1371/journal.pone.0011019.g003
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caused by the high level of IFN-c in culture, since IFN-c up-
regulates IDO in macrophages and dendritic cells (34).
In spleen cells of P-mice, treatment with the agonistic anti-4-1BB
mAb did not significantly modify Ag85B-induced release of IL-2, IL-6,
MIP-1band TNF-a, similarly to IFN-cproduction, and did not induce
release of IL-10, IL-4, TGF-b, IL-17 and XCL-1 (Table 5), supporting
again the unresponsiveness of these T cells to ligands for 4-1BB.
4-1BB ligation on purified CD4
+ T cells of NP-mice
stimulated with Ag85B protein inhibits release of IL-10
and MIP-1b, but not IFN-c: requirement of CD8
+ T cells
for 4-1BB-mediated IFN-c inhibition
Since Ag85B-stimulated CD4
+ T cells of NP-mice expressed the
4-1BB molecule, the effects induced by a direct engagement of this
TNF-receptor on these cells were investigated. Therefore,
antigenic recall studies were performed on purified CD4
+ T cells
cultured on a feeder of CD3
+ T cell-depleted spleen cells of naive
mice. In addition to IFN-c (as previously shown in Fig. 1), IL-10
and MIP-1b were also secreted in such co-culture upon Ag85B
protein stimulation (Fig. 6 A–C). Treatment with an agonistic anti-
4-1BB mAb, while increasing IFN-c release, significantly reduced
CD4
+ T cell-mediated-secretion of IL-10 and MIP-1b (Fig. 6 A–C).
The effects induced by 4-1BB ligation on release of these cytokines
were attributable to CD4
+ T cells since CD3
+ T cell-depleted
spleen cells of naive mice used as feeder did not release IFN-c and
IL-10 in response to Ag85B protein and/or to agonistic anti-4-1BB
mAb, and released only a low amount of MIP-1b not modified by
4-1BB treatment (Fig. 6 A–C). As previously shown in Fig. 1A,
addition of purified CD8
+ T cells of NP-mice to the co-culture
significantly reduced IFN-c secretion by Ag85B-stimulated CD4
+
T cells (Fig. 6 A). Treatment of these CD4
+/CD8
+ T cell-co-
culture with the agonistic anti-4-1BB mAb resulted in a further
IFN-c inhibition (50.263.5 versus 3663 in the presence or absence
of 4-1BB ligation, respectively) (Fig. 6 A), suggesting that 4-1BB
ligation on 4-1BB
+CD8
+ T cells enhanced the suppressive effects
exerted by CD8
+ T cells on CD4
+ T cell-mediated IFN-c release. A
low, almost undetectable release of IFN-c by purified CD8
+ T cells
was found upon Ag85B stimulation, and IFN-c secretion was not
significantly modified by 4-1BB ligation, further confirming that
IFN-c released by spleen cells upon antigenic recall was mainly due
to CD4
+ T cells. Differently from what observed for IFN-c release,
Table 2. Effects of 4-1BB ligation in spleen cells of NP- and P-















unstimulated 1.560.5 1.160.05 2.360.3 1.760.4
Ag85B 11.760.3** 3.560.5** 13.461.3** 11.561.7**
P-mice
unstimulated 1.0560.05 0.260.1 1.360.13 0.3560.05
Ag85B 4.560.6** 0.260.1 3.160.7 0.4560.05
Unfractionated spleen cells of P- or NP-mice were cultured with Ag85B protein
(5 mg/ml). After 3 or 6 days of culture cells were labeled with the following
labelled mAb: CD4 PE-Cy7, CD8 PE-Cy7, CD3 FITC and 4-1BB PE. Cell surface
molecule expression was analyzed by flow cytometry as described in Materials
and Methods. The results are presented as mean 6 SEM of the percentage of
CD4
+ T cells or CD8
+ T cells positive for 4-1BB. Pooled data of 3 independent
experiments are shown.
**, p,0.01, statistical significance for differences between groups Ag85B vs
unstimulated determined by a two-tailed Student’s t-test.
doi:10.1371/journal.pone.0011019.t002
Table 3. Effects of 4-1BB ligation in spleen cells of NP- and P-
mice stimulated with Ag85B protein on expression of





CD25 CD38 CD233 CD44
high
NP-mice
unstimulated 14.062.0 17.060.6 10.061.0 15.560.5
Ag85B/control IgG 40.560.5# 44.661.3# 4963.0# 41.560.5#
Ag85B/anti-4-1BB
mAb
30.561.51 29.660.91 35.561.51 26.560.51
P-mice
unstimulated 10.660.6 16.060.1 5.560.5 14.060.1
Ag85B/control IgG 20.760.6# 24.660.3# 14.560.5# 21.061.0#
Ag85B/anti-4-1BB
mAb
23.061.0 25.061.7 14.061.0 22.560.5
Unfractionated spleen cells of P- or NP-mice were cultured with Ag85B protein
(5 mg/ml) in the presence of IgG2a control Ab or agonist anti-4-1BB mAb (5 mg/
ml). After 6 days of culture cells were labeled with the indicated mAbs. Cell
surface molecule expression was analyzed by flow cytometry as described in
Materials and Methods. The results are presented as mean 6 SEM of the
percentage of CD4
+ T cells staining for the indicated markers. Pooled data of 3
independent experiments are shown.
#, 1 statistical significance (p,0.05 or ,0.01) for differences between groups
determined by ANOVA and Bonferroni-type multiple t-test (# Ag85B/control
IgG vs unstimulated; 1 Ag85B/control IgG vs Ag85B/anti-4-1BB mAb).
doi:10.1371/journal.pone.0011019.t003
Table 4. Effects of 4-1BB ligation in spleen cells of NP- and P-
mice stimulated with Ag85B protein on expression of





CD25 CD38 CD233 CD44
high
NP-mice
unstimulated 10.561.5 12.461.0 14.461.2 7.361.4
Ag85B/control IgG 9.662.1 13.361.0 32.861.1# 8.661.6
Ag85B/anti-4-1BB
mAb
961.2 13.161.0 22.461.31 12.561.2
P-mice
unstimulated 8.061.5 15.561.6 6.061.0 9.760.8
Ag85B/control IgG 6.661.2 15.560.2 15.360.3# 7.760.9
Ag85B/anti-4-1BB
mAb
6.760.8 1661.0 15.560.5 8.961.0
Unfractionated spleen cells of P- or NP-mice were cultured with Ag85B protein
(5 mg/ml) in the presence of IgG2a control Ab or agonist anti-4-1BB mAb (5 mg/
ml). After 6 days of culture cells were labeled with the indicated mAbs. Cell
surface molecule expression was analyzed by flow cytometry as described in
Materials and Methods. The results are presented as mean 6 SEM of the
percentage of CD8
+ T cells staining for the indicated markers. Pooled data of 3
independent experiments are shown.
#, 1 statistical significance (p,0.05 or ,0.01) for differences between groups
determined by ANOVA and Bonferroni-type multiple t-test (# Ag85B/control
IgG vs unstimulated; 1 Ag85B/control IgG vs Ag85B/anti-4-1BB mAb).
doi:10.1371/journal.pone.0011019.t004
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+ T cells neither affected release of IL-10 and
MIP-1b by Ag85B-stimulated CD4
+ T cells nor modified the
reduction of IL-10 and MIP-1b secretion caused by a direct
engagement of 4-1BB on Ag85B-activated CD4
+ T cells (Fig. 6 B
and C). Purified CD8
+ T cells released low amount of MIP-1b
upon Ag85B stimulation that remained unaltered following 4-1BB
ligation while IL-10 was undetectable in CD8
+ T cell culture
supernatants (Fig. 6 B and C).
Antigenic recall experiments performed with purified CD4
+
and/or CD8
+ T cells of P-mice indicated that treatment with
agonistic anti-4-1BB mAb did not influence secretion of IFN-c and
MIP-1b by CD4
+ T cells nor the CD8
+T cell-mediated inhibition
of IFN-c release by CD4
+ T cells (data not shown). These results
are in agreement with the lack o low 4-1BB expression on Ag85B-
stimulated T cells of P-mice.
In vivo antigenic stimulation induces expression of 4-1BB
on Ag85B-specific CD8
+ T cells and 4-1BB ligation inhibits
the antigen-mediated IFN-c production and expansion of
CD4
+ T cells from NP-mice
To evaluate the effects of in vivo 4-1BB triggering on Ag85B-
specific CD4
+ and CD8
+ T cells, adoptive transfer experiments
with spleen cells of NP-mice were performed. Spleen cells from
NP-mice (CD45.2
+) were injected into C57BL/6Ly5.1 recipient
mice (expressing CD45.1 leukocyte antigen). On post-injection
(p.i.) day 1, mice were inoculated s.c. with 10 mg of recombinant
Ag85B protein and then i.p. with 150 mg agonistic anti-mouse
4-1BB mAb or with 150 mg rat IgG2a isotype control mAb. On
p.i. day 3, mice were again injected with 150 mg agonistic anti-
mouse 4-1BB mAb or with 150 mg rat IgG2a isotype control Ab.
As controls, a group of mice adoptively transferred with
splenocytes from NP-mice was treated with neither antigen Ag85B
nor mAbs, and two groups of mice, not inoculated with splenocytes
from NP-mice, received only the treatment with Ag85B and mAbs
as descrived above. On p.i. day 10, all mice were sacrificed and
spleens were harvested for immunological studies (Fig. 7 A).
In spleen cells of mice adoptively transferred with cells from NP-
mouse the frequency of CD4
+ and CD8
+ T cells originating from
NP-mice following antigenic stimulation in vivo with Ag85B protein
in the presence of anti-4-1BB mAb or control IgG2a mAbs was
analyzed by gating lymphocytes positive for CD45.2. We found
that injection of Ag85B into mice induced a significant expansion
of Ag85B-specific CD4
+ T cells (Fig. 7 B, Table 6). Moreover, in
vivo Ag85B treatment, induced the expression of 4-1BB on both
CD4
+ and CD8
+ T cells (Fig. 7 C, Table 6), suggesting that in vivo
4-1BB engagement could modulate their responses. In fact,
treatment with anti-4-1BB mAb in vivo significantly reduced the
percentage of CD4
+ T cells responding to Ag85B treatment.
Although the increase of CD8
+ T cell frequency was not
statistically significant, in vivo 4-1BB ligation significantly reversed
the ratio of CD4
+ and CD8
+ T cells (0.6460.3 vs 1.260.01 in
mice injected with Ag85B and anti-4-1BB mAb compared with
mice injected with Ag85B and control IgG2a mAb, respectively
(Fig. 7 B, Table 6). This indicates an expansion of CD8
+ T cells at
the expense of CD4
+ T cells in mice treated with anti-4-1BB mAb.
To better clarify whether in vivo 4-1BB ligation downgrades the
action of Ag85B-specific CD4
+ T cells while expanding CD8
+ T
cells, we also performed ex vivo antigenic recall experiments with
spleen cells of mice adoptively transferred with cells from NP-
mouse. After 4 days of culture the percentage of proliferating
CD8
+CD45.2
+T cells, both in unstimulated and ex vivo Ag85B-
restimulated splenocytes, was significantly enhanced in anti-4-1BB
mAb-treated mice (Fig. 7 D). On the contrary, the anti-4-1BB
Figure 4. Effects of 4-1BB ligation in spleen cells of NP-mice stimulated with Ag85B protein on CD4
+ and CD8
+ T cell proliferation.
Pooled spleen cells of NP- or P-mice, were labelled with CFSE as described in Materials and Methods and then stimulated with Ag85B protein (5 mg/
ml) in the presence of agonistic anti-4-1BB mAb (5 mg/ml) or rat IgG2a control Ab (5 mg/ml) for 4 days. At this time point cells were labelled with CD4-
PE and CD8-PerCP and analyzed by flow cytometry as described in Materials and Methods. The percentage indicates the number of replicating CD4
+
or CD8
+ T cells. Plots, gated on CD4
+ or CD8
+ T cell in the lymphocyte-gate, are representative of one experiments out of 3.
doi:10.1371/journal.pone.0011019.g004
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Pooled spleen cells of NP-mice, unfractionated or depleted of CD4
+ or CD8
+ T cells by using magnetic beads as described in Materials and Methods
(panels B and C), were re-stimulated with Ag85B protein (5 mg/ml) in the presence of agonistic anti-4-1BB mAb (5 mg/ml) or rat IgG2a control Ab
(5 mg/ml). Culture supernatants were harvested at 48 h for IL-2, IL-4, at 72 h for IFN-c, IL-6, IL-10, MIP-1b, TGF-b1, TNF-a, XCL-1 and at 96 h for IL-17
detection by specific quantitative sandwich ELISA Kits. Data are presented as mean of 3 independent experiments for panels A, B, and C. Error bars
indicate SEM. The level of statistical significance for differences between Ag85B stimulation in the presence of IgG2a control Ab or agonistic anti-4-
1BB mAb were determined by a two-tailed Student t test (*, p,0.05; **, p,0.01). In panel D, spleen cells after 2 days of culture and an overnight
incubation with brefeldin A were stained with CD4-PE-Cy5 and then intracellular stained with PE anti-IL-10 Ab as reported in Material and Methods.
Cells were then analyzed by flow cytometry. Dot plot were generated after gating on live CD4
+ T lymphocytes and show frequency of IL-10-
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proliferating CD4
+CD45.2
+T cells (Fig. 7 D) as well as the
percentage of IFN-c-producing CD4
+CD45.2
+T cells responding
to ex vivo antigenic re-stimulation (Fig. 7 E). Moreover, IFN-c
accumulation in culture supernatants, both in unstimulated and
re-stimulated ex vivo with Ag85B protein spleen cell culture, was
significantly reduced in anti-4-1BB mAb-treated mice (Fig. 7 F).
The IFN-c released in the cultures was mainly released by cells
originating from NP-mice (Fig. 7 F). Altogether these data indicate
that in vivo 4-1BB ligation reduced antigen-mediated-activation of
Ag85B-specific CD4
+ T cells while expanding CD8
+ T cells of NP-
mice, in keeping with the results of the in vitro experiments (see
above).
Discussion
Dampening the drawbacks of elevated antigen-specific IFN-c
secretion by CD4
+ T cells without affecting the protective IFN-c
response is a difficult challenge in TB research, particularly to
generate a strongly immunogenic though safe vaccine. In a murine
model of TB, combined DNA/protein immunization with the
mycobacterial antigen Ag85B (NP-mice) increases IFN-c produc-
tion by antigen-specific CD4
+ T cells but reduces protection from
challenge relative to the marked protection seen in mice
immunized with DNA alone (P-mice) (10, 36). Here we report
that both protective and non-protective Ag85B-immunizations
generate antigen-specific CD8
+ T cells which, in ex vivo
experiments, suppress IFN-c-production by Ag85B-specific
CD4
+ T cells. Signals via the TNF-receptor 4-1BB down-
modulate, via CD8
+ T cells, the high-level of IFN-c production
by Ag85B-specific CD4
+ T cell associated with poor protection in
NP-mice while preserving the low IFN-c response that is
associated with protective immunity in P-mice. The observed
inhibition of memory IFN-c-secreting CD4
+ T cell in NP-mice
was likely due to the induction, upon Ag85B stimulation, of 4-1BB
expression selectively on suppressor CD8
+ T cells of NP-mice.
Thus, the 4-1BB capability of discriminating between low and
high antigen-specific CD4
+ T-cell-mediated IFN-c responses could
be instrumental to find novel strategies based on T cells and co-
stimulatory signals to down-regulate the effects of elevated antigen-
specific IFN-c responses associated with TB pathology and its
negative impact on vaccine protection. As a matter of fact,
knowledge of T-cell co-stimulatory molecules on MTB immunity
and their potential use as new therapeutic targets is still lacking. In
addition, in vivo 4-1BB ligation reduced the activation, IFN-c
production and expansion of CD4
+ T cells of NP-mice re-
stimulated in vivo with Ag85B, suggesting that the inhibitory
phenomenon observed in vitro can also occur in vivo.
CD8
+ T cells have a recognized, direct role in protection against
TB through their cytotoxic activity on MTB-infected cells [48].
The main finding of this paper strongly indicate that CD8
+ T cells
may have an additional role in TB as regulator of CD4
+ T cell-
mediated responses, which are mainly implicated in protection
against MTB infection [3,4]. A role for CD8
+ Treg cells was
postulated to explain increased IFN-c production by antigen-
specific murine CD4
+ T cells following CD8
+T cell-depletion ex
vivo [10] and in vivo [44]. Here we provide the first evidence of
antigen-induced suppressor CD8
+ T cells generated in vivo that
inhibit CD4
+ T cell proliferation and IFN-c secretion ex vivo. These
suppressor CD8
+ T cells were found in the spleen of both NP- and
P-mice suggesting that they are an intrinsic component of the
response to immunization. Indeed, splenic CD8
+ T cells of naive
mice did not show any regulatory activity. Moreover, while
suppressor CD8
+ T cells were generated both in P- and NP-mice,
4-1BB ligation suppressed the CD4
+ T cell-mediated IFN-c
response only in NP-mice. This suppressive effect was linked to the
induction, upon Ag85B protein stimulation, of 4-1BB receptor
expression only on CD8
+ T cells of NP-mice. Thus, CD8
+ T cells
of NP-mice responded to 4-1BB ligands while CD8
+ T cells of P-
mice were insensitive to 4-1BB ligation because they did not
express 4-1BB molecules. Consistent with these results is the
enhancement of antigen-specific cell proliferation of CD8
+ T cells
of NP-mice but not of P-mice following agonistic anti-4-1BB mAb
treatment.
The elevated level of IFN-c found in spleen cell cultures of NP-
mice upon Ag85B protein stimulation may be responsible for the
selective expression of 4-1BB on the surface of CD8
+ T cells of NP-
mice. In fact, during chronic inflammation, 4-1BB receptor
expression was up-regulated on CD8
+ T cell surface by
inflammatory mediators including IFN-c [49,50]. Therefore
expression of 4-1BB on suppressor CD8
+ T cells in mice producing
elevated amount of IFN-c may be a self-regulatory mechanism
that curtails excessive, antigen-driven IFN-c response in MTB
infection. This hypothesis is in agreement with the high expression
of 4-1BB induced by Ag85B stimulation in vivo on CD8
+ T cells of
NP-mice and expansion of these cells upon in vivo anti-4-1BB mAb
treatment. The role played by 4-1BB in regulating CD8
+ Treg
cells deserves to be further investigated in TB and also in other
infectious diseases. In fact, induction of pathogen-specific CD8
+
Treg cells, involved in regulating both pathogen eradication and
immunopathology [51,52], have been described in various
bacterial [53], viral [54–56] and parasitic infections [57].
producing cells. In panel E, the IDO-inhibitor, 1-MT (400 mM), or neutralizing anti-TGF-b1.2 mAb (2 mg/ml) were added simultaneously to culture of
spleen cells stimulated with Ag85B protein (5 mg/ml) in the presence of agonistic anti-4-1BB mAb (5 mg/ml) or rat IgG2a control Ab (5 mg/ml). Culture
supernatants were harvested at 72 h for IFN-c detection by specific quantitative sandwich ELISA Kits. Percent of 4-1BB-mediated inhibition of Ag85B-
induced IFN-c release is shown in round brackets.
doi:10.1371/journal.pone.0011019.g005
Table 5. Effects of 4-1BB ligation in Ag85B-activated spleen







IL-2 0601 4 4 660 97650
IL-4 0600 600 60
IL-6 0604 1 614 37617
IL-10 0600 600 60
IL-17 0600 600 60
TNF-a 0603 2 664 4 66
MIP-1 b 30620 24366195 27706140
TGF2b17 1 3 6102 702698 7686130
XCL-1 0600 600 60
Unfractionated spleencellsofP-micewereculturedwith Ag85Bprotein(5 mg/ml)
in the presence of IgG2a control Ab or agonist anti-4-1BB mAb (5 mg/ml). Culture
supernatants were harvested at 48 h for IL-2, IL-4; at 72 h for IL-6, IL-10, XCL-1,
MIP-1b,T G F - b1, TNF-a and at 96 h for IL-17 detection by specific quantitative
sandwich ELISA Kits. The results are presented as mean 6 SEM in pg/ml for
cytokine detection. Pooled data of 3 independent experiments are shown.
doi:10.1371/journal.pone.0011019.t005
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Apparently, none of the mechanisms thus far proposed to explain
inhibition of IFN-c secreting CD4
+ T cells applies to our findings.




been proposed to suppress antigen-mediated CD4
+ T cell
responses in PPD
+ responders via inhibition of Ca
2+ flux [24].
Even though we found release of MIP-1b by CD8
+ T cells upon
Ag85B stimulation and 4-1BB ligation, the inhibitory action of
soluble MIP-1b did not match MIP-1b release by Ag85B-activated
CD4
+ T cells nor the reduced, total MIP-1b accumulation in
spleen cells upon 4-1BB ligation. In addition, the high CD38
expression on CD4
+ T cells might have counteracted MIP-1b
inhibition of Ca
2+ flux by activating Ca
2+ influx through an
ADPR-gated cation channel [37]. Second, release of IL-10 and
TGF-b, which are main mediators of CD8
+ and CD4
+ Treg cells
[42,43,51] are not relevant for suppression of IFN-c production in
our experiments. Agonist anti-4-1BB mAb did not increase the
basal TGF-b accumulation found in spleen cultures and a
neutralizing anti-TGF-b mAb was ineffective in contrasting 4-
1BB effects on IFN-c release. 4-1BB engagement did not induce
secretion of IL-10 by CD8
+ T cells, and even down-regulated the
secretion of IL-10 by CD4
+ T cells. Taking into account that IL-
10-secreting CD4
+ Treg isolated from TB patients have been often
considered a poor prognostic factor [19–23], the IL-10-indepen-
dent mechanisms of IFN-c regulation described in this paper may
constitute a protective mechanism that limits dangerous inflam-
mation without being associated with the anergy induced by IL-10
in TB patients. Third, XCL-1, a chemokine produced by activated
CD8
+ T cells during the chronic stage of MTB infection, which
negatively affects production of IFN-c by CD4
+ T cells [44], was
not released by CD8
+ T cells of NP-mice either upon Ag85B
stimulation or following 4-1BB ligation. Fourth, the inability of an
IDO inhibitor to counteract 4-1BB regulatory effects indicate that
IDO accumulation in macrophages and dendritic cells - a
mechanism which suppress CD4
+ T cell responses in experimental
uveoretinitis and rheumatoid arthritis through release of IFN-c by
4-1BB-activated T cells [34,47] - was not activated by Ag85B-
specific CD8
+ T cells and was not involved in control of Ag85B-
induced IFN-c response.
The adoptive transfer experiments clearly demonstrated that in
vivo treatment with anti-4-1BB mAb inhibited antigen-mediated
activation, IFN-c production and expansion of Ag85B-specific
CD4
+ T cells of NP-mice. Although the cellular and molecular
mechanisms operating in vivo remain to be elucidated, an at least
partial involvement of CD8
+ T cells is suggested by the antigen-
mediated expression of 4-1BB on CD8
+ T cells, and by their
proliferation following 4-1BB ligation in vivo. Interestingly, it has
been recently reported that 4-1BB ligation in vivo expanded a subset
of CD8
+ T cells involved in suppression of the recall response to
staphylococcal enterotoxin A-specific CD4
+ T cells [58].
Besides inhibition of IFN-c production, agonist anti-4-1BB mAb
treatment of splenocytes of NP-mice induced several changes in
Ag85B-specific CD4
+ T cells consistent with reduced cellular
activation. Cell proliferation was lowered, expression of activation
marker such as CD38, CD25, CD44 and CD233 was down-
modulated, and secretion of MIP-1b and IL-10 was also
decreased. The 4-1BB-mediated de-activation of Ag85B-specific
CD4
+ T cells occurred via CD8
+ T suppressor cells only for IFN-c
modulation while inhibition of IL-10 and MIP-1b secretion was
attributable to a direct triggering of 4-1BB on surface of CD4
+ T
cells. Altogether these data indicate that in NP-mice, Ag85B-
responding CD4
+ T cells are a non-homogeneous population or
they are regulated by distinct pathways which are differentially
Figure 6. 4-1BB ligation on purified CD4
+ T cells of NP-mice
inhibits Ag85B-induced release of IL-10 and MIP-1b, but not
IFN-c: requirement of CD8
+ T cells for 4-1BB-mediated IFN-c
inhibition. Untouched purified CD4
+ T cells (5610
4 cells/well) and
CD8
+ T cells (3610
4 cells/well) obtained by negative magnetic bead
separation as described in Materials and Methods from spleen cells of
NP-mice were cultured, alone or together (using the CD4/CD8 ratio of
1:0.6 as found in fresh spleen cells) on a feeder of CD3
+ T cell-depleted
spleen cells of naive mice (1.5610
5 cells/well). Cells were re-stimulated
with Ag85B protein (5 mg/ml) in the presence of agonistic anti-4-1BB
mAb or rat IgG2a control Ab (5 mg/ml each). Culture supernatants were
harvested at at 72 h for IFN-c, (panel A), MIP-1b (panel B) and IL-10
(panel C) detection by specific quantitative sandwich ELISA Kits. Data
are presented as mean of 4 independent experiments. Error bars
indicate SEM. The level of statistical significance for differences were
determined by a two-tailed Student’s t-test (*, p,0.05; **, p,0.01)
between Ag85B stimulation in the presence of rat IgG2a control Ab or
agonistic anti-4-1BB mAb (panels A–C) and between Ag85B-induced
responses (both in the presence or absence of agonist anti-4-1BB mAb)
by CD4
+ T cells alone and co-cultured with CD8
+ T cells ( panel A).
doi:10.1371/journal.pone.0011019.g006
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CD4
+ T cells, 4-1BB treatment reduced the release of excessive
and dangerous IFN-c, inhibited secretion of IL-10 and MIP-1b,
which are often associated with TB susceptibility [19,59] while
preserved the low production of IL-2 and TNF-a, two cytokines
which are essential for granuloma maintenance [60,61] and are
expressed, together with IFN-c, in polyfunctional T cells
associated with protection from MTB infection [62].
Overall, the novel regulatory effects shown by agonistic 4-1BB
ligands on modulation of potentially dangerous responses of CD4
+
T cells specific for Ag85B - an antigen actively secreted by
replicating MTB and proposed as a candidate sub-unitTB vaccine -
open novel strategies for intervention in TB pathology and
vaccination through T-cell co-stimulatory-based molecular target-
ing.Although the role playedby 4-1BB in vivo duringMTB infection
needs further investigations, this receptor could be effectively
involved in the immunological responses against mycobacterial
infection since expression of CD137, the human counterpart of 4-
1BB, was found on a sub-population of the T-lymphocytes
infiltrating lung tuberculous granulomas in patients with TB [63].
Materials and Methods
Ethics Statement
The handling of mice were conducted in accordance with the
regulations set forward by the institutional animal care committee
of the Italian Ministry of Health, and in compliance with
European Community Directive 86/609 and the U.S. Association
for Laboratory Animal Care recommendations for the care and
use of laboratory animals.
Immunizations
C57BL/6 female mice were supplied as specific pathogen-free
mice by Harlan (Udine, Italy) and were maintained in specific-
pathogen-free conditions. Mice, 6 to 8 week old, were immunized.
Fifty mg of plasmid Ag85B-encoding DNA, prepared as previously
reported [10], was injected i.m. in 50 ml PBS into the hind leg. On
the dorsum of the mice, 10 mg of recombinant Ag85B protein,
prepared as previously reported [10], was co-administered s.c.
Recombinant Ag85B protein was free of physiologically significant
levels of endotoxin, as measured by LAL system. Mice were
immunized twice with Ag85B-encoding DNA at 2-week intervals (P-
mice). Some DNA-primed-mice were boosted with Ag85B protein
twice at 2-week intervals (NP-mice). Four weeks after the last
immunization, spleens were harvested for immunological studies.
Spleen cell preparation and separation of lymphocytes
Single cell suspensions from pooled spleens (4 mice per group,
4 separate experiments) were applied to Falcon 2360 cell strainers
(BD Discovery Labware, San Diego, CA), centrifuged, separated
into aliquots and frozen. From spleen cell suspension, isolated
Figure 7. Effects of in vivo Ag85B stimulation and 4-1BB ligation on CD4
+ and CD8
+ T cells of NP-mice. Spleen cells from NP-mice were
adoptively transferred into C57BL/6Ly5.1 recipient mice accordingly to the scheme shown in panel A. 10
7 splenocytes from NP-mice (CD45.2
+ cells)
were adoptively transferred i.v. into C57BL/6Ly5.1 recipient mice (expressing CD45.1 leukocyte antigen). On p.i. day 1, mice were inoculated s.c. with
10 mg of recombinant Ag85B protein and then i.p. with 150 mg agonistic anti-mouse 4-1BB mAb or with 150 mg rat IgG2a isotype control mAb. On p.i.
day 3, mice were again injected with 150 mg agonistic anti-mouse 4-1BB mAb or with 150 mg rat IgG2a isotype control Ab. As controls, a group of
mice adoptively transferred with splenocytes from NP-mice was treated with neither antigen Ag85B nor mAbs, and two groups of mice, not
inoculated with splenocytes from NP-mice, received only the treatment with Ag85B and mAbs as descrived above. On p.i. day 10, fresh spleen cell
recovered from mice adoptively transferred with NP-mice and treated in vivo with Ag85B and mAb were labelled with CD45.2-FITC, CD4-PE, CD8-
PerCP, 4-1BB-PE, CD4-PerCPCy5.5 and analyzed by flow cytometry. In panel B, the percentage indicates the frequency of CD4
+ and CD8
+ T cells
originating from NP-mice and in panel C the percentage of those CD4
+ and CD8
+ T cells expressing 4-1BB. Plots, gated on CD45.2
+ cells in the
lymphocyte-gate, are representative of 1 out of 3 mice per group. Spleen cells of C57BL/6Ly5.1 were then used for antigenic recall ex vivo
experiments. Cells were re-stimulated ex vivo with Ag85B protein (5 mg/ml). In panel D spleen cells, labelled with CFSE at day 0 as described in
Materials and Methods, after 4 days of culture were stained with CD4-PE, CD8-PerCP and CD45.2-APC and analyzed by flow cytometry. The




+ T cells. In panel E the frequency of IFN-c-producing CD4
+CD45.2
+ T cells
were measured by FACS analysis after 4 days of culture and an overnight incubation with brefeldin A on cells labelled with CD4-PerCP-Cy5.5, CD45.2-
FITC and then intracellular stained with PE anti-IFN-c Ab. Cells were then analyzed by flow cytometry. In panel F the amount of IFN-c released in the
culture supernatants after 4 days was detected by a commercial ELISA kit. The data has been reported as the mean of 3 individual determinations for
each group. Error bars indicate SEM. The level of statistical significance for differences between unstimulated and ex vivo antigen-stimulated spleen
cells of mice adoptively transferred with cells from NP-mice and treated in vivo with Ag85B protein in the presence of IgG2a control Ab or agonistic
anti-4-1BB mAb were determined by a two-tailed Student t test (*, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0011019.g007
Table 6. Effects of Ag85B stimulation and 4-1BB ligation on in vivo frequency of CD4
+ and CD8
+ T cells and 4-1BB expression of
cells from NP-mice adoptively transferred into C57BL/6Ly5.1 recipient mice.
CD45.2







+ T cells CD8
+ T cells T cells T cells
none 21.260.5 21.860.5 2.860.1 2.460.1
Ag85B/control IgG 25.860.3# 22.160.8 10.161.0# 15.460.9#
Ag85B/anti-4-1BB mAb 16.760.51 25.861.3 7.160.61 12.360.8
C57BL/6Ly5.1 mice adoptively transferred with 10
7 spleen cells from NP-mice (cells CD45.2
+) were treated or not with antigen Ag85B and mAbs as described in Materials
and Methods. Slpeen cells were harvested on post-infection day 10, stained with CD45.2-FITC, CD4-PE, CD8-PerCP, CD4PerCPCy5.5 and 4-1BB-PE mAbs andt h e n
analyzed by flow cytometry. The data, obtained by gating CD45.2
+ cells on lymphocyte population, show the frequency of CD4
+ and CD8
+ T cells originating from NP-
mice and the percentage of T cells expressing 4-1BB. The results are presented as mean 6 SEM of 3 mice per group.
#, 1 statistical significance for differences between groups determined by ANOVA and Bonferroni-type multiple t-test (# Ag85B/control IgG vs none; 1 Ag85B/control
IgG vs Ag85B/anti-4-1BB mAb).
doi:10.1371/journal.pone.0011019.t006
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+ or CD8
+ T cells and the corresponding CD4- or CD8-
depleted spleen cell populations, were purified by negative
selection using specific mouse CD4
+ or CD8
+ T cell isolation
kits (Miltenyi Biotec Inc. Auburn, CA), in accordance with
manufacturer’s instructions. The purity of isolated CD4
+ or
CD8
+ T cells ranged between 94% and 96% as estimated by
FACS analysis.
Spleen cell cultures
Cells isolated from spleens of immunized mice, either
unfractionated or CD4- and CD8-depleted, were cultured at a
density 1.4610
6cells/ml in 96-well plates for cell proliferation
and cytokine detection or in 24-well plates for cytokine detection
and flow cytometry analysis in RPMI-1640 supplemented with
10% heat-inactivated FBS, 2 mM L-glutamine, 10 mM HEPES
buffer, 50mM2 - b-ME, 50 U/ml penicillin and 50 mg/ml
streptomycin (complete RPMI, cRPMI). Cells were stimulated
with 5 mg/ml Ag85B protein or 0.1 mg/ml agonistic anti-mouse
CD3e mAb (BD Pharmingen, San Jose, CA) in the presence or
absence of 5 mg/ml agonistic anti-mouse 4-1BB/TNFRSF9/
CD137 mAb (clone 158321) (R&D System, Inc. Minneapolis,
MN) or rat IgG2a isotype control Ab (clone 544479) (R&D
System, Inc). In some culture, the IDO-inhibitor, 1-methyltryp-
tophan (1-MT) (Sigma-Aldrich, Saint Louis, MO) 400 mMo r
neutralizing anti-TGFb1 mAb (clone 9016) (R&D System, Inc.)
were also added.
In other experiments, untouched purified CD4
+ or CD8
+ T
cells were magnetically isolated from the specific mouse CD4
+ or
CD8
+ T cell isolation kits, (Miltenyi Biotec), in accordance with
manufacturer’s instructions. Purified untouched CD4
+ T cells
(5610
4 cells/well) or purified untouched CD8
+ T cells (3610
4
cells/well) were cultured on a feeder of spleen cells recovered from
naı ¨ve unvaccinated mice and depleted of CD3
+ T lymphocyte by a
magnetic separation through a PE-isolation kit (Miltenyi Biotec)
(1.5610
5 cells/well). Co-cultures of purified untouched CD4
+ and
CD8
+ T cells were performed at a CD4/CD8 ratio of 1:0.6, which
reflected the CD4/CD8 ratio observed by FACS analysis in fresh
splenocytes. Cells were stimulated with 5 mg/ml Ag85B protein
with or without 5 mg/ml agonistic anti-mouse 4-1BB mAb or
5 mg/ml rat IgG2a control Ab.
Cytokine detection in culture supernatants
Supernatants of cultured cells were harvested at 2, 3, 4 and 5
days and assayed for IFN-c, IL-10, IL-4, IL-2, IL-6, IL-17, TNF-
a,T G F - b,M I P - 1 b and XCL-1 by specific quantitative sand-
wich ELISA (mouse Quantikine, R&D System, Inc. or Ray-
Biotech, Inc. Norcross, GA), in accordance with manufacturer’s
instructions.
Flow cytometric analysis
Fresh spleen cells or cells cultured in 24 well plates for 4 or 6
d a y s ,w e r ew a s h e dw i t h1 %B S A ,0 . 1 %N a N 3 in PBS 16(FACS
buffer), and stained for 20 min at 4uC with the following mAbs:
PE-Cy5 anti-mouse CD4, PerCPCy5.5 anti-mouse CD4, PE-Cy7
anti-mouse CD8 (eBioscience, San Diego CA), FITC anti-mouse
CD11c (Serotec LTD, Oxford, UK), PerCP anti-mouse CD8,
FITC anti-mouse CD3, PE anti-mouse 4-1BB, FITC anti-mouse
CD38, FITC anti-mouse CD25, PE anti-mouse CD233, FITC
anti-mouse CD44, PE anti-mouse CD62L and FITC anti-mouse
CD45.2 (BD Biosciences Pharmingen). Cells were washed and
analyzed on a FACScan flow cytometer (Beckton Dickinson
Immunocytometry System, San Jose, CA) with the Cell Quest
software program. Staining of samples with isotype controls was
used as a reference to determine positive and negative
populations. For intracellular cytokine staining, spleen cells were
treated overnight with 10 mg/ml of brefeldin A (Sigma-Aldrich),
an inhibitor of protein transport from endoplasmic reticulum to
the Golgi apparatus. Then cells were stained for 20 min at 4uC
with PE-Cy5 anti-mouse CD4, PerCPCy5.5 anti-mouse CD4,
FITC anti-mouse CD45.2 or PercPE anti-mouse CD8, washed
and fixed for 5 min with 4% paraformaldehyde. Cells were
washed and stained with FITC- anti-mouse IFN-c,P E - a n t i -
mouse IFN-c, PE anti-mouse IL-10 or isotype controls (BD
Biosciences Pharmingen) in FACS buffer with 0.5% saponin for
45 min at R.T. Cells were then washed in FACS buffer with
0.1% saponin and subsequently with FACS buffer with 0.01%
saponin and then analyzed on a FACScan flow cytometer with
the Cell Quest software program.
Cell proliferation by CFSE staining
Spleen cells (10
7 cells/ml) were stained with 5(6)-Carboxy-
fluorescein diacetate N-succinimidyl ester (CFSE) (Invitrogen
Life Technologies) at 1 mM in PBS 1%FBS for 10 min at 37uC
in the dark. Cells were washed and cultured in 96-well plates,
as previously described, for 4 days. After the incubation time,
cells were washed with FACS buffer, and stained for 20 min at
4uC with PE anti-mouse CD4, PerCP anti-mouse CD8, APC
anti-mouse CD45.2 (BD Biosciences Pharmingen) or the
isotype controls. Cells were washed and analyzed on a









+T cells; these T cells are CD45.2
+) were
adoptively transferred intravenously via caudal vein injection into
C57BL/6Ly5.1 recipient mice (same strain of mice expressing
CD45.1 instead of CD45.2 on their leukocytes). On postinjection
(p.i.) day 1, mice (3 mice each group) were inoculated s.c. with
10 mg of recombinant Ag85B protein and then i.p. with 150 mg
agonistic anti-mouse 4-1BB/TNFRSF9/CD137 mAb (clone
158321) or with 150 mg rat IgG2a isotype control mAb (clone
544479). On p.i. day 3, mice were again injected with 150 mg
agonistic anti-mouse 4-1BB mAb or with 150 mg rat IgG2a isotype
control Ab. As controls, a group of mice adoptively transferred
with splenocytes from NP-mice was treated with neither antigen
Ag85B nor mAbs, and two groups of mice, not inoculated with
splenocytes from NP-mice, received only the treatment with
Ag85B and mAbs as descrived above. On p.i. day 10, all mice
were sacrificed and spleens were harvested for immunological
studies.
Acknowledgments
We thank Maria Laura Gennaro for helpful discussion. We are grateful to
Federico Giannoni and Lara Brunori, for providing the plasmid DNA-85B,
to Maria Elena Laguardia for Ag85B protein purification, and to Giovanni
Piccaro and Antonio Di Virgilio for mouse housing and technical
assistance.
Author Contributions
Conceived and designed the experiments: CP. Performed the experiments:
CP SV. Analyzed the data: CP SV AC. Contributed reagents/materials/
analysis tools: CP AC. Wrote the paper: CP AC.
4-1BB and IFN-c in TB
PLoS ONE | www.plosone.org 14 June 2010 | Volume 5 | Issue 6 | e11019References
1. World Health Organization (WHO). Global tuberculosis control: surveillance,
planning, financing. WHO/HTM/TB 2008.393. Geneva: WHO, 2008.
2. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC (2009) Tuberculosis vaccine
research: the impact of immunology. Curr Opin Immunol 21: 331–338.
3. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, et al. (1993)
Disseminated tuberculosis in interferon-c gene-disrupted mice. J Exp Med 178:
2243–2249.
4. Jung YJ, Ryan L, LaCourse R, North RJ (2005) Properties and protective value
of the secondary versus primary T helper type 1 response to airbone
Mycobacterium tuberculosis infection in mice. J Exp Med 201: 1915–1924.
5. Dannenberg AM, Jr., Collins FM (2001) Progressive pulmonary tuberculosis is
not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs,
but is due to a continuous host response to mycobacterial products. Tuberculosis
81: 229–242.
6. Gonzales-Juarrero M, Turner J, Basaraba RJ, Belisle JT, Orme IM (2002) Florid
pulmonary inflammatory responses in mice vaccinated with antigen-85 pulsed
dendritic cells and challenged by aereosol with Mycobacterium tuberculosis. Cell
Immunol 220: 13–19.
7. Ehlers S, Benini J, Held HD, Roeck C, Alber G, et al. (2001) abT cell receptor
positive cells and IFN-c, but not inducible nitric oxide synthase, are critical for
granuloma necrosis in a mouse model of mycobacteria-induced pulmonary
immunopathology. J Exp Med 194: 1847–1859.
8. Elias D, Aruffo H, Britton S (2005) PPD induced in vitro IFN-c production is not
a reliable correlate of protection against Mycobacterium tuberculosis. Tran R Soc
Trop Med Hyg 99: 363–368.
9. Leal IS, Smedegard B, Andersen P, Appelberg R (2001) Failure to induce
enhanced protection against tuberculosis by increasing T cell-dependent
interferon-c. Immunol 104: 157–161.
10. Palma C, Iona E, Giannoni F, Pardini M, Brunori L, et al. (2007) The Ag85B
protein of Mycobacterium tuberculosis may turn a protective immune response
induced by Ag85B-DNA vaccine into a potent but non protective Th1 immune
response in mice. Cell Microbiol 9: 1455–1456.
11. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, et al. (2006)
Mucosal administration of Ag85B-ESAT-6 protects against infection with
Mycobacterium tuberculosis and boots prior bacillus Calmette-Guerin immunity.
J Immunol 177: 6353–6360.
12. Doherty TM, Olsen AW, Weischenfeldt J, Huygen K, D’Souza S, et al. (2004)
Comparative analysis of different vaccine constructs expressing defined antigens
from Mycobacterium tuberculosis. J Infect Dis 190: 2146–2153.
13. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, et al. (2008) A new
recombinant bacilli Calmette-Guerin vaccine safely induces significantly
enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis
198: 1491–501.
14. Boesen H, Jensen BN, Wilcke T, Andersen P (1995) Human T-cell responses to
secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun 63:
1491–1497.
15. Schwander SK, Torres M, Sada E, Carranza C, Ramos E, et al. (1998)
Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar
lymphocytes during active pulmonary tuberculosis. J Infect Dis 178: 1434–1445.
16. Mittru ¨cker HW, Steinhoff U, Ko ¨hler A, Krause M, Lazar D, et al. (2007) Poor
correlation between BCG vaccination-induced T cell responses and protection
against tuberculosis. Proc Natl Acad Sci USA 104: 12434–12439.
17. Koch R (1890) Weitere mittheilungen uber ein heilmittel gegen tuberkulose.
Dtsch Med Wochenschr 16: 1029–1032.
18. Quinn KM, Rich FJ, Goldsack LM, de Lisle GW, Buddle BM, et al. (2008)
Accelerating the secondary immune response by inactivating CD4
+CD25
+ T
regulatory cells prior to BCG vaccination does not enhance protection against
tuberculosis. Eur J Immunol 38: 695–705.
19. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, et al. (2000) IL-10-
producing T cells suppress immune responses in anergic tuberculosis patients.
J Clin Invest 105: 1317–1325.
20. Delgado JC, Tsai EY, Thim S, Baena A, Boussiotis VA, et al. (2002) Antigen-
specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis
patients from rural Cambodia. Proc Natl Acad Sci USA 99: 7576–7581.
21. Li L, Lao SH, Wu CY (2007) Increased frequency of CD4
+CD25high Treg cells
inhibit BCG-specific induction of IFN-c by CD4
+ T cells from TB patients.
Tuberculosis 87: 526–534.
22. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A (2006) Regulatory T
cells are expanded in blood and disease sites in patients with tuberculosis.
Am J Respir Crit Care Med 173: 803–810.




regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with
active disease. Clin Immunol 123: 50–59.
24. Joosten SA, van Meijgaarden KE, Savage ND, de Boer T, Triebel F, et al. (2007)
Identification of a human CD8
+ regulatory T cell subset that mediates
suppression through the chemokine ligand 4. Proc Natl Acad Sci USA 104:
8029–8034.
25. Kwon BS, Weissman SM (1989) cDNA sequences of two inducible T-cell genes.
Proc Natl Acad Sci USA 86: 1963–1967.
26. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, et al. (1993) Inducible T cell
antigen 4-1BB. Analysis of expression and function. J Immunol 150: 771–781.
27. Watts TH (2005) TNF/TNFR family members in costimulation of T cell
responses. Annu Rev Immunol 23: 23–68.
28. Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, et al. (2001) 4-
1BB ligand induces cell division, sustains survival, and enhances effector function
of CD4 and CD8 T cells with similar efficacy. J Immunol 167: 1313–1324.
29. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, et al. (1997) 4-
1BB costimulatory signals preferentially induce CD8
+ T cell proliferation and
lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186:
47–55.
30. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, et al. (1997)
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate
established tumors. Nat Med 3: 682–685.
31. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, et al. (2002) Provision of
antigen and CD137 signaling breaks immunological ignorance, promoting
regression of poorly immunogenic tumors. J Clin Invest 109: 651–659.
32. Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, et al. (2007) Ex
vivo expansion of CD4
+CD25
+FoxP3
+ T regulatory cells based on synergy
between IL-2 and 4-1BB signaling. J Immunol 179: 7295–7304.
33. Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK (1999)
Anti-4-1BB monoclonal antibodies abrogate T-cell dependent humoral immune
responses in vivo through the induction of helper T cell anergy. J Exp Med 190:
1535–1540.
34. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, et al. (2004) 4-1BB-mediated
immunotherapy of rheumatoid arthritis. Nat Med 10: 1088–1094.
35. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL (2008) Multi-
layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.
Trends Pharmacol Sci 29: 383–390.
36. Palma C, Iona E, Giannoni F, Pardini M, Brunori L, et al. 2008. The LTK63
adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting
vaccination against Mycobacterium tuberculosis infection by dampening IFN-c
response. Vaccine 26: 4237–43.
37. Lund FE (2006) Signaling properties of CD38 in the mouse immune system:
enzyme-dependent and –independent roles in immunity. Mol Med 12: 328–333.
38. Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA (2002)
Phenotypic analysis of the murine CD4-related glycoprotein, CD233 (LAG-3).
Eur J Immunol 32: 2255–2263.
39. Huang CT, Workman CJ, Flies X, Pan D, Marson AL, et al. (2004) Role of
LAG-3 in regulatory T cells. Immunity 21: 503–513.
40. Huard B, Tournier M, Hercend T, Triebel F, Faure F (1994) Lymphocyte-
activation gene3/major histocompatibility complex class II interaction modu-
lates the antigenic response of CD4
+ T lymphocytes. Eur J Immunol 24:
3216–3221.




+ T cells: a population of T cells with immune regulatory
activities in vitro. Eur J Immunol 28: 3435–3447.
42. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, et al.
(2006) Interleukin-10-secreting type 1 regulatory cells in rodents and humans.
Immunol Rev 212: 28–50.
43. Zhang L, Yi H, Xia XP, Zhao Y (2006) Transforming growth factor–b:a n
important role in CD4
+CD25
+regulatory T cells and immune tolerance.
Autoimmunity 39: 269–276.
44. Ordway D, Higgings DM, Sanchez-Campillo J, Spencer JS, Henao-Tamayo M,
et al. (2007) XCL1 (lymphotactin) chemokine produced by activated CD8 T cells
during the chronic stage of infection with Mycobacterium tuberculosis negatively
affects production of IFN-c by CD4 T cells and participates in granuloma
stability. J Leukoc Biol 82: 1221–1229.
45. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-
23 and IL-17 in the establishment of protective pulmonary CD4
+ T cell
responses after vaccination and during Mycobacterium tuberculosis challenge.
Nat Immunol 8: 369–377.
46. Werninghaus K, Babiak A, Gross O, Ho ¨lscher C, Dietrich H, et al. (2009)
Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium
tuberculosis vaccination requires FcRc–Syk–Card9–dependent innate immune
activation. J Exp Med 206: 89–97.
47. Choi BK, Asai T, Vinay DS, Kim YH, Kwon BS (2006) 4-1BB-mediated
amelioration of experimental uveoretinitis is caused by indoleamine 2,3
dioxygenase-dependent mechanisms. Cytokine 34: 233–242.
48. Stenger S, Mazzaccarro RJ, Uyemura K, Cho S, Barnes PF, et al. (1997)
Differential effects of cytolytic T cell subsets on intracellular infection. Science
276: 1684–1687.
49. Olofsson PS, Sodersrom LA, Wagsater D, Sheikine Y, Ocaya P, et al. (2008)
CD137 is expressed in human atherosclerosis and promotes development of
plaque inflammation in hypercholesterolemic mice. Cirulation 117: 1292–1301.
50. Giscombe R, Wang XB, Kakoulidou M, Lefvert AK (2006) Characterization of
the expanded T-cell population in patients with Wegener’s granulomatosis.
J Intern Med 260: 224–230.
51. Mills KHG (2004) Regulatory cells: friend or foe in immunity to infection? Nat
Rev Immunol 4: 841–855.
52. Belkaid Y, Rouse BT (2005) Natural regulatory T cells in infectious disease. Nat
Immunol 6: 353–360.
4-1BB and IFN-c in TB
PLoS ONE | www.plosone.org 15 June 2010 | Volume 5 | Issue 6 | e1101953. Jones HP, Tabor L, Sun X, Woolard MD, Simecka JW (2002) Depletion of
CD8
+ T cells exacerbates CD4
+ Th cell-associated inflammatory lesions during
murine mycoplasma respiratory disease. J Immunol 168: 3493–3501.
54. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, et al. (2004)
Hepatic expansion of a virus-specific regulatory CD8
+ T cell population in
chronic hepatitis C virus infection. J Clin Invest 113: 963–972.
55. Garba ML, Pilcher CD, Bingham AL, Eron J, Frelinger JA (2002) HIV antigens
can induce TGF-b1-producing immunoregulatory CD8
+ T cells. J Immunol
168: 2247–2254.
56. Haynes LM, Vanderlgut CL, Dalcanto MC, Melvold RW, Miller SD (2000)
CD8
+ T cells from Theiler’s virus-resistant BALB/cByJ mice down-regulate
pathogenic virus-specific CD4
+ T cells. J Neuroimmunol 106: 43–52.
57. Ormer FM, de Souza JB, Riley EM 2003. Differential induction of TGF-b
regulates proinflammatory cytokine production and determined the outcome of
lethal and nonlethal Plasmodium yoelii infections. J Immunol 171: 5430–5436.
58. Kim YH, Choi BK, Kang WJ, Kim KH, Kang SW, et al. (2009) IFN-c-
indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-
mediated immune suppression in vivo. J Leukoc Biol 85: 817–825.
59. Jamieson SE, Miller EN, Black GF, Peacock CS, Cordell HJ, et al. (2004)
Evidence for a cluster of genes on chromosome 17q11-q21 controlling
susceptibility to tuberculosis and leprosy in Brazilians. Genes Immun 5: 46–57.
60. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, et al. (1995) Tumor
necrosis factor-a is required in the protective immune response against
Mycobacterium tuberculosis infection in mice. Immunity 2: 561–572.
61. Bean AG, Roach DR, Briscoe H, France MP, Korner H, et al. (1999) Structural
deficiencies in granuloma formation in TNF gene-targeted mice underlie the
heightened susceptibility to aereosol Mycobacterium tuberculosis infection,
which is not compensated for by lymphoyoxin. J Immunol 162: 3504–11.
62. Aagard C, Thanh Hoang TTK, Izzo A, Billeskov R, Troudt JL, et al. (2009)
Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against
Mycobacterium tuberculosis is highly dependent on the antigen dose. PloS ONE 4:
e5930.
63. Boussaud V, Soler P, Moreau J, Goodwin RG, Hance AJ (1998) Expression of
three members of the TNF-R family of receptors (4-1BB, Lymphotoxin-beta
receptor and Fas) in human lung. Eur Respir J 12: 926–931.
4-1BB and IFN-c in TB
PLoS ONE | www.plosone.org 16 June 2010 | Volume 5 | Issue 6 | e11019